Fred Balis, MD
Internal Medicine · Chesterfield, MONPI 1861447625
Payments from drug & device makers
Across 34 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$193
- Pfizer$98
- AbbVie$75
- EMD Serono, Inc.$33
- Amgen$32
- Astellas Pharma US Inc$21
- plus $94 from 6 others
What the payments were for
- Food & beverage$545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $193 |
| Pfizer | 6 | $98 |
| AbbVie(2 entities) | 5 | $75 |
| EMD Serono, Inc. | 2 | $33 |
| Amgen | 2 | $32 |
| Astellas Pharma US Inc | 1 | $21 |
| Gilead | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Merck | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$545 in reported general payments places this provider in the 65th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 34 | $48,741 |
| TrulicityDulaglutide | 20 | $23,318 |
| FarxigaDapagliflozin Propanediol | 11 | $11,129 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,203 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,954 |
| Gabapentin | 70 | $1,295 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,188 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,051 |
| Atorvastatin Calcium | 156 | $947 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 21 | $869 |
| Omeprazole | 47 | $781 |
| Amlodipine Besylate | 149 | $623 |
| Famotidine | 25 | $604 |
| Metoprolol Succinate | 17 | $590 |
| Fluticasone Propionate | 25 | $581 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chesterfield
- Jianbo WangChesterfield$643K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.